ADC Therapeutics’ (ADCT) “Buy” Rating Reaffirmed at HC Wainwright

ADC Therapeutics is a biopharmaceutical company that specializes in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. The company's lead product candidate, ADCT-301, is currently being evaluated in clinical trials for the treatment of relapsed/refractory Hodgkin lymphoma.

On Wednesday, HC Wainwright reissued their buy rating on shares of ADC Therapeutics NYSEADCT, indicating that they continue to view the company's prospects positively. The firm currently has a $9.00 target price on the stock.

In addition to HC Wainwright, other analysts have also issued research reports about the stock. For example, Royal Bank of Canada lifted their price objective on shares of ADC Therapeutics, indicating that they believe the company's stock is undervalued and has significant potential for growth.

Overall, the positive outlook from HC Wainwright and other analysts suggests that investors may view ADC Therapeutics as a promising investment opportunity in the biopharmaceutical industry.